Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04081220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Completed to Active, Not Recruiting
    • Study completion date: Dec 20, 2023 to Dec 20, 2026
    • Secondary endpoints expanded, about 7 words
    v11
  2. Results first posted: May 20, 2025
    • Primary endpoint revised
    • Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Jan 2025 to Dec 20, 2023
    v10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 9
    • Primary completion date changed from estimate of Jan 2024 to Dec 20, 2023
    • Site details revised
    v9
  4. Primary completion date: Jan 2023 to Jan 2024
    • Study completion date: Jan 2024 to Jan 2025
    v8
  5. Primary completion date: Jan 31, 2022 to Jan 2023
    • Study completion date: Dec 2023 to Jan 2024
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2020 to Apr 9, 2020
    v5
  3. Start date: Jan 31, 2020 to Mar 2020v4
  4. Start date: Oct 31, 2019 to Jan 31, 2020
    • Primary completion date: Oct 31, 2021 to Jan 31, 2022
    • Study completion date: Dec 2022 to Dec 2023
    v3
  5. Primary endpoint revised
    • Eligibility criteria expanded, about 16 words
    • Study title expanded, about 6 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Trial Details
NCT Number NCT04081220
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Conditions
(from sponsor)		 Thrombocythemia, Essential
Related terms Thrombocythemia, Essential
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov